At The Portland Clinic, we’ve been treating the people in our community with trust, kindness and understanding for nearly 100 years. For us, that means asking good questions and paying close attention to your answers. Working hard to find out where you...
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.
If you think all generic pharmaceutical distributors are alike, it’s time to think again. We’re TOP RX, a leading national generic distributor that helps more than 5,000 pharmacies keep prices low on more than 2,800 generic pharmaceuticals. We call our company “TOP” for several reasons. We bring value to your business in many ways including our technological solutions, guaranteed product credibility and competitive pricing.
Lumate Health is a Cognitive Behavioral Teletherapy Platform treating teenagers and young adults with anxiety-related mental health disorders.
Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.